REG - Novacyt S.A. - Half-year trading update

Novacyt SAAnnouncement

Tue 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250729:nRSc8821Sa&default-theme=true

RNS Number : 8821S  Novacyt S.A.  29 July 2025

 

Novacyt S.A.

("Novacyt", the "Company" or the "Group")

 

Half-year trading update

 

Paris, France, and Manchester, UK - 29 July 2025 - Novacyt S.A. (EURONEXT
GROWTH: ALNOV; AIM: NCYT), the international molecular diagnostics company
with a broad portfolio of integrated technologies and services, announces an
unaudited trading update for the six months ended 30 June 2025.

 

Financial Highlights

 

·    Unaudited Group statutory revenue for H1 2025 expected to be circa
£9.8 million (H1 2024: £10.0 million - restated to remove any IT-IS
International revenue due to its treatment under IFRS 5)

o  The underlying Group revenue has grown by circa 2% (4% on a constant
currency basis), excluding the impact of the Taiwan service laboratory
divestment

·    Encouraging growth delivered by the Company's clinical segment,
generating sales of £6.9 million

·    NIPT technologies up over 10% year-on-year to £2.4 million

·    Geographically, the APAC region achieved year-on-year growth of circa
9%, driven by the continued strong demand for the Company's Reproductive
Health range of products

o  Cash position at 30 June 2025 was £23.8 million (31 December 2024: £30.5
million), and the Group remains debt free and confident that the cash runway
is sufficient to reach EBITDA profitability

 

Post Period Highlights

 

·    LightBench® Discover, a high-precision 3-in-1 instrument for genomic
research labs conducting long-read sequencing, was successfully launched in
July 2025

 

Commenting Lyn Rees, Chief Executive Officer, said: "We are pleased with the
Company's performance to date, following an extensive period of restructuring
and consolidation and remain focused on executing growth to see the Company
through to EBITDA profitability. We are proud to announce the successful
launch of LightBench® Discover, putting Novacyt at the forefront of genomic
research."

 

 This announcement contains inside information for the purposes of Article 7
of Regulation (EU) 596/2014.

 

 

Contacts

 

 Novacyt SA                                                              https://novacyt.com/investors (https://novacyt.com/investors/)
 Lyn Rees, Chief Executive Officer                                        Via Walbrook PR
 Steve Gibson, Chief Financial Officer

 SP Angel Corporate Finance LLP (Nominated Adviser and Broker)                                             +44 (0)20 3470 0470
 Matthew Johnson / Charlie Bouverat (Corporate Finance)

 Vadim Alexandre / Rob Rees (Corporate Broking)

 Deutsche Numis (Joint Broker)                                                                             +44 (0)20 7260 1000
 Freddie Barnfield / Duncan Monteith / Michael Palser

 Allegra Finance (French Listing Sponsor)       +33 (1) 42 22 10 10

                                             r.durgetto@allegrafinance.com (mailto:r.durgetto@allegrafinance.com) /
 Rémi Durgetto / Yannick Petit                 y.petit@allegrafinance.com

 Walbrook PR (Financial PR & IR)                                         +44 (0)20 7933 8780 or novacyt@walbrookpr.com

 Paul McManus / Lianne Applegarth                                        +44 (0)7980 541 893 / +44 (0)7584 391 303

 Alice Woodings                                                           +44 (0)7407 804 654

 

About Novacyt Group (www.novacyt.com)

Novacyt is an international molecular diagnostics company providing a broad
portfolio of integrated technologies and services, primarily focused on the
delivery of genomic medicine. The Company develops, manufactures, and
commercialises a range of molecular assays and instrumentation to deliver
workflows and services that enable seamless end-to-end solutions from sample
to result across multiple sectors including human health, animal health and
environmental.

 

The Company is divided into three business segments:

 

 Clinical             Broad portfolio of human clinical in vitro diagnostic products, workflows and
                      services focused on three therapeutic areas:

                      ·    Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy
                      tests

                      ·    Precision Medicine: DPYD genotyping assay

                      ·    Infectious Diseases: Winterplex, multiplex winter respiratory PCR
                      panel

 Instrumentation      Portfolio of next generation size selection DNA sample preparation platforms
                      and rapid PCR machines, including:

                      ·    Ranger® Technology: automated DNA sample preparation and target
                      enrichment technology

                      ·    genesig q16 and q32 real-time quantitative PCR (qPCR) instruments

 Research Use Only    Range of services for the life sciences industry:

                      ·    Design, manufacture, and supply of high-performance qPCR assays and
                      workflows for use in human health, agriculture, veterinary and environmental,
                      to support global health organisations and the research industry

                      ·    Pharmaceutical research services: whole genome sequencing (WGS) /
                      whole exome sequencing (WES)

 

Novacyt is headquartered in Le Vésinet in France with offices in the UK
(Manchester), Singapore, the US and Canada and has a commercial presence in
over 65 countries. The Company is listed on the London Stock Exchange's AIM
market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV").

 

For more information, please refer to the website: www.novacyt.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTBRGDRRSDDGUI